What is Zacks Research’s Forecast for STERIS Q2 Earnings?

STERIS plc (NYSE:STE) – Research analysts at Zacks Research reduced their Q2 2026 earnings estimates for STERIS in a research note issued to investors on Tuesday, September 16th. Zacks Research analyst Team now forecasts that the medical equipment provider will earn $2.37 per share for the quarter, down from their previous forecast of $2.82. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.57 EPS, Q4 2026 earnings at $2.85 EPS, FY2026 earnings at $10.13 EPS, Q1 2027 earnings at $2.46 EPS, Q2 2027 earnings at $2.86 EPS, Q3 2027 earnings at $2.79 EPS, Q4 2027 earnings at $2.64 EPS, FY2027 earnings at $10.75 EPS, Q1 2028 earnings at $3.01 EPS and FY2028 earnings at $12.21 EPS.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.02. The company had revenue of $1.40 billion during the quarter, compared to analysts’ expectations of $1.36 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.03 earnings per share.

Several other research analysts have also recently commented on the stock. Jefferies Financial Group initiated coverage on shares of STERIS in a report on Thursday, May 29th. They set a “hold” rating and a $263.00 target price for the company. KeyCorp increased their target price on shares of STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a report on Tuesday, July 22nd. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, Morgan Stanley increased their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Stock Up 0.8%

STERIS stock opened at $250.78 on Thursday. The stock has a market capitalization of $24.70 billion, a PE ratio of 38.40 and a beta of 0.95. STERIS has a twelve month low of $200.98 and a twelve month high of $253.00. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The company has a 50 day moving average of $238.76 and a 200-day moving average of $233.85.

Hedge Funds Weigh In On STERIS

Hedge funds have recently bought and sold shares of the company. Spurstone Advisory Services LLC bought a new position in STERIS in the 2nd quarter valued at about $29,000. Geneos Wealth Management Inc. increased its holdings in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares during the period. Grove Bank & Trust increased its holdings in STERIS by 4,733.3% in the 1st quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 142 shares during the period. Zions Bancorporation National Association UT bought a new position in STERIS in the 1st quarter valued at about $37,000. Finally, ORG Wealth Partners LLC bought a new position in STERIS in the 1st quarter valued at about $43,000. 94.69% of the stock is owned by institutional investors.

Insider Buying and Selling at STERIS

In related news, CAO Karen L. Burton sold 7,900 shares of the firm’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.73, for a total transaction of $1,909,667.00. Following the transaction, the chief accounting officer directly owned 5,994 shares of the company’s stock, valued at approximately $1,448,929.62. This trade represents a 56.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cynthia L. Feldmann sold 3,495 shares of the firm’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.56, for a total transaction of $844,252.20. Following the completion of the transaction, the director directly owned 705 shares in the company, valued at approximately $170,299.80. This represents a 83.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,709 shares of company stock valued at $4,546,940 in the last three months. 1.07% of the stock is owned by insiders.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 26th. Investors of record on Thursday, September 4th will be given a dividend of $0.63 per share. This is a positive change from STERIS’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, September 4th. STERIS’s payout ratio is 38.59%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.